- Home
- CHCO vs MNKD Comparison
CHCO vs MNKD Comparison
Compare CHCO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCO
- MNKD
- Stock Information
- Founded
- CHCO 1957
- MNKD 1991
- Country
- CHCO United States
- MNKD United States
- Employees
- CHCO N/A
- MNKD N/A
- Industry
- CHCO Major Banks
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- CHCO Finance
- MNKD Health Care
- Exchange
- CHCO Nasdaq
- MNKD Nasdaq
- Market Cap
- CHCO 1.7B
- MNKD 1.9B
- IPO Year
- CHCO N/A
- MNKD 2004
- Fundamental
- Price
- CHCO $119.68
- MNKD $6.01
- Analyst Decision
- CHCO Hold
- MNKD Buy
- Analyst Count
- CHCO 4
- MNKD 6
- Target Price
- CHCO $117.25
- MNKD $8.92
- AVG Volume (30 Days)
- CHCO 71.3K
- MNKD 2.7M
- Earning Date
- CHCO 01-31-2025
- MNKD 02-25-2025
- Dividend Yield
- CHCO 2.64%
- MNKD N/A
- EPS Growth
- CHCO N/A
- MNKD N/A
- EPS
- CHCO 7.80
- MNKD 0.08
- Revenue
- CHCO $289,546,000.00
- MNKD $267,200,000.00
- Revenue This Year
- CHCO N/A
- MNKD $45.45
- Revenue Next Year
- CHCO $0.38
- MNKD $16.45
- P/E Ratio
- CHCO $15.35
- MNKD $75.81
- Revenue Growth
- CHCO 0.71
- MNKD 51.35
- 52 Week Low
- CHCO $97.50
- MNKD $3.17
- 52 Week High
- CHCO $137.28
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- CHCO 46.41
- MNKD 37.75
- Support Level
- CHCO $117.92
- MNKD $5.98
- Resistance Level
- CHCO $121.80
- MNKD $6.32
- Average True Range (ATR)
- CHCO 2.76
- MNKD 0.21
- MACD
- CHCO 0.36
- MNKD -0.04
- Stochastic Oscillator
- CHCO 77.20
- MNKD 20.55
About CHCO City Holding Company
City Holding Co is a financial holding company. It provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, saving accounts, credit card and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance, technology products, and others. These products and services are provided to commercial banking, consumer banking, mortgage banking, wealth management, and trust services.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.